前列腺癌药物市场规模、份额和成长分析（按药物类别、分销管道和地区）- 产业预测 2025-2032

2023 年前列腺癌药物市场规模价值 135 亿美元，预计将从 2024 年的 146.3 亿美元增长到 2032 年的 279 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.4%。

由于人口老化和早期诊断意识的增强，全球前列腺癌药物市场正在迅速发展。治疗方法的重大进步使患者能够获得一系列治疗方法，包括手术、放射线治疗、化疗、荷尔蒙疗法疗法、免疫疗法和标靶治疗，加速了市场的成长。精准医疗的趋势正在日益增强，从而能够提供更个人化的治疗选择。製药公司和研究机构等领先的行业参与者正在合作创新该领域。儘管存在高成本、副作用和需要更好的生物标记等治疗挑战，但包括新型药物传输系统和人工智慧整合在内的创新方法正在改变诊断和治疗决策。联合治疗和免疫疗法、基因疗法等替代疗法的兴起可能会进一步重塑前列腺癌药物模式。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

前列腺癌药物市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概况
• 荷尔蒙疗法
  • 黄体激素释放激素 (LHRH) 拮抗剂
  • 泽泻
  • 戈纳克斯
  • 黄体激素释放激素 (LHRH)促效剂
  • 亮丙瑞林
  • Zoladex
  • 艾利加德
  • 十甲哌啶
  • 万塔斯
  • 其他的
  • 抗雄激素
  • 赞迪
  • 卡索得
• 化疗
  • Taxotere
  • 杰夫塔纳
• 免疫疗法
  • Provenge
• 标靶治疗
  • 佐菲戈
• 其他的

前列腺癌药物市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 药局和药房
• 网路药局

前列腺癌治疗药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• AbbVie（US）
• Amgen（US）
• AstraZeneca（UK）
• Bayer AG（Germany）
• Johnson & Johnson（US）
• Pfizer Inc.（US）
• Novartis AG（Switzerland）
• Merck & Co.（US）
• Sanofi（France）
• Roche（Switzerland）
• Bristol-Myers Squibb（US）
• Eli Lilly and Company（US）
• GlaxoSmithKline（UK）
• Takeda Pharmaceutical Company Limited（Japan）
• Astellas Pharma Inc.（Japan）
• MSD（Merck & Co., Inc.）（US）
• Bayer Healthcare（Germany）
• Daiichi Sankyo Company, Limited（Japan）

结论和建议

Prostate Cancer Therapeutics Market size was valued at USD 13.5 billion in 2023 and is poised to grow from USD 14.63 billion in 2024 to USD 27.9 billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).

The Global Prostate Cancer Therapeutics Market is rapidly evolving, driven by an aging population and increased awareness of early diagnosis. Significant treatment advancements have led to enhanced market growth, with diverse modalities including surgery, radiation, chemotherapy, hormone therapy, immunotherapy, and targeted therapies available for patients. The trend toward precision medicine is gaining traction, allowing for more personalized treatment options. Key industry players, such as pharmaceutical companies and research organizations, are collaborating to innovate within the sector. Despite challenges like high costs, adverse effects, and the need for better biomarkers, innovative approaches, including novel drug delivery systems and AI integration, are transforming diagnostics and treatment decisions. The rise of combination therapies and alternative methods like immunotherapy and gene therapy are set to further reshape the prostate cancer therapeutics landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Therapeutics Market Segments Analysis

Global Prostate Cancer Therapeutics Market is segmented by Drug Class, Distribution Channel and Region. Based on Drug Class, the market is segmented into Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Prostate Cancer Therapeutics Market

A significant catalyst for the Global Prostate Cancer Therapeutics Market is the rising aging population. With advancing age, individuals face a heightened risk of developing prostate cancer, thereby expanding the pool of patients in need of effective treatment options. This demographic shift, especially prevalent in developed areas, plays a crucial role in driving the growth and demand for therapies aimed at combatting prostate cancer. As the number of older adults increases, so too does the necessity for innovative therapeutic solutions, further propelling the market forward in response to this essential healthcare need.

Restraints in the Prostate Cancer Therapeutics Market

A significant limitation in the Prostate Cancer Therapeutics market is the prohibitive cost of treatments. The financial burden stemming from various modalities, including diagnosis, surgery, radiation, chemotherapy, hormone therapies, and targeted treatments, can be substantial. This high expense presents considerable challenges for both patients and healthcare systems, potentially restricting access to essential care, especially in areas with constrained healthcare resources or among patients lacking sufficient insurance coverage. Consequently, these financial hurdles may impede market expansion and adversely affect patient outcomes, highlighting the need for more affordable therapeutic options in this sector.

Market Trends of the Prostate Cancer Therapeutics Market

In the Prostate Cancer Therapeutics market, a significant trend is the rising emphasis on precision medicine. This approach seeks to customize treatment strategies based on individual patient characteristics, including genetic profiles, biomarkers, and specific disease factors. As research advances in molecular profiling technologies and the understanding of genetic mutations linked to prostate cancer, there is a growing shift towards personalized, targeted therapies. This trend not only aims to improve treatment efficacy but also to mitigate side effects, leading to enhanced patient outcomes. Consequently, pharmaceutical companies are increasingly investing in tailored therapies, reflecting a paradigm shift in prostate cancer management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Prostate Cancer Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Hormonal Therapy
  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
  • Zytiga
  • Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
  • Lupron
  • Zoladex
  • Eligard
  • Decapeptyl
  • Vantas
  • Others
  • Anti-Androgen
  • Xtandi
  • Casodex
• Chemotherapy
  • Taxotere
  • Jevtana
• Immunotherapy
  • Provenge
• Targeted Therapy
  • Xofigo
• Others

Global Prostate Cancer Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Prostate Cancer Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD (Merck & Co., Inc.) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Healthcare (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations